Obesity drug development - CBI's 2nd Annual Summit.
Heal
David J
DJ
RenaSci Consultancy Ltd, BioCity, Nottingham, NG1 1GF, UK. inform@renasci.co.uk
D017667:Adipocytes / Q000187:drug effects; D000818:Animals; D019440:Anti-Obesity Agents / Q000494:pharmacology* / Q000627:therapeutic use; D063385:Cannabinoid Receptor Modulators / Q000502:physiology; D004195:Disease Models, Animal; D015195:Drug Design; D004970:Estrone / Q000031:analogs & derivatives / Q000494:pharmacology; D005227:Fatty Acids / Q000378:metabolism; D006801:Humans; D009765:Obesity / Q000188:drug therapy; D009829:Oleic Acids / Q000494:pharmacology; D010084:Oxidation-Reduction; D010880:Piperidines / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors; D000077285:Rimonabant
D019440:Anti-Obesity Agents; D063385:Cannabinoid Receptor Modulators; D005227:Fatty Acids; D009829:Oleic Acids; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D004970:Estrone; C108709:oleoyl-estrone; D000077285:Rimonabant